Technology area: Biotechnology & Pharmaceuticals
94 pending office actions • 43 clients • 88 examiners • 47 art units • 0 of 94 (0%) have an AI response strategy ready
BOZICEVIC, FIELD & FRANCIS LLP has 95 pending office actions in Biotechnology & Pharmaceuticals and 8797 career applications. The figures reflect a large recorded portfolio and a substantial current prosecution workload in the reported technical area.
The resolved allowance rate is 75.76%, with an average of 3.96 office actions per allowance. The allowance figure is lower than the profile's application volume might imply from workload alone, while the response average indicates repeated examination activity before allowance. Clients should evaluate both the scale of the docket and the need for sustained prosecution work when considering this profile.
Based on the USPTO statutory response window for each pending office action. 23 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 23 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 2 (2%) |
| §101 + other | 10 (11%) |
| §103 only | 17 (18%) |
| §102 only | 6 (6%) |
| §112 only | 7 (7%) |
| Double-patenting + other | 19 (20%) |
| Multi-statute (no §101) | 33 (35%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAQ, SHAFIQUL | 2 | 64.8% | +55.2% |
| ZOU, NIANXIANG | 2 | 64.0% | +25.0% |
| ESSEX, LAURA ANN | 2 | 60.0% | +35.8% |
| MCCORMICK, CATHERINE LYNN | 2 | 52.3% | +39.8% |
| ORDAZ, CHRISTIAN JOSE | 2 | 66.7% | +78.6% |
| RYAN, DOUGLAS CHARLES | 2 | 38.2% | +48.4% |
| BRAZIN, JACQUELINE | 1 | 65.6% | +52.7% |
| UCHITEL, EMILY RUTH ABIGAIL | 1 | — | — |
| COOPER, JONATHAN EPHRAIM | 1 | 46.4% | +31.8% |
| CABRAL, ROBERT S | 1 | 62.8% | +32.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18036133 | CLUBROOT RESISTANCE IN RAPESEED BRASSICA NAPUS | WILLIAMS, KEITH RICHARD | 210d overdue |
| 18265410 | Plants With Sr2-mediated Stem Rust Resistance | ORDAZ, CHRISTIAN JOSE | 4d overdue |
| 18702756 | Wearable Non-Invasive Central Nervous System Neuromodulator and Methods for Using Same | KOWALKOWSKI, FIONA MARGARET | 2d overdue |
| 17618870 | USE OF AMINOTHIOL COMPOUNDS AS CEREBRAL NERVE OR HEART PROTECTIVE AGENT | MOORE, SUSANNA | 55d |
| 18271663 | POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF | NIEBAUER, RONALD T | 60d |
| 17848313 | SYSTEMS AND METHODS FOR TARGETING CANCER CELLS | SKELDING, ZACHARY S | 63d |
| 18274152 | Genetically Modified Hepatocyte Populations | YU, MISOOK | 84d |
| 19540475 | Immunoassays for Buprenorphine and Metabolites | HAQ, SHAFIQUL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17630875 | SYNTHETIC IMMUNE CELLS AND METHODS OF USE THEREOF | RYAN, DOUGLAS CHARLES | 74d overdue |
| 18265410 | Plants With Sr2-mediated Stem Rust Resistance | ORDAZ, CHRISTIAN JOSE | 4d overdue |
| 17544527 | Screening for Inhibitors of Prostaglandin E Synthase 3 Useful for Treatment of Prostate Cancer | RYAN, DOUGLAS CHARLES | 12d |
| 18039840 | Antibody Delivery | MCCORMICK, CATHERINE LYNN | 26d |
| 19540475 | Immunoassays for Buprenorphine and Metabolites | HAQ, SHAFIQUL | — |
| 19372053 | Compositions, Devices, Systems, and Methods for Using a Nanopore | BRAZIN, JACQUELINE | — |
| 18871774 | Motion Capture and Biomechanical Assessment of Goal-Directed Movements | COOPER, JONATHAN EPHRAIM | — |
| 18942149 | Promoting Hair Growth and Treatment of Hair Loss or Excessive Hair Shedding | CABRAL, ROBERT S | — |
| Art Unit | Apps |
|---|---|
| 3791 | 5 |
| 1675 | 5 |
| 1658 | 4 |
| 3792 | 4 |
| 1671 | 4 |
| 1618 | 3 |
| 1622 | 3 |
| 1641 | 3 |
| 1672 | 3 |
| 1644 | 3 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19540475 | Immunoassays for Buprenorphine and Metabolites | Ark Diagnostics, Inc. | HAQ, SHAFIQUL | 1678 | §103§112 | Final Rejection | — | Pending | Feb 13, 2026 |
| 19372053 | Compositions, Devices, Systems, and Methods for Using a Nanopore | The Regents of the University of California | BRAZIN, JACQUELINE | 1798 | §103 | Final Rejection | — | Pending | Oct 28, 2025 |
| 18993797 | Methods and Systems for Detecting Stroke | The Regents of the University of California | UCHITEL, EMILY RUTH ABIGAIL | §101§103§112 | Non-Final OA | — | Pending | Jan 13, 2025 | |
| 18871774 | Motion Capture and Biomechanical Assessment of Goal-Directed Movements | The Regents of the University of California | COOPER, JONATHAN EPHRAIM | 3791 | §101§102§103§112 | Non-Final OA | — | Pending | Dec 04, 2024 |
| 18942149 | Promoting Hair Growth and Treatment of Hair Loss or Excessive Hair Shedding | Samson Clinical Pty Ltd. | CABRAL, ROBERT S | 1614 | §103 | Non-Final OA | — | Pending | Nov 08, 2024 |
| 18930210 | COMPOSITIONS AND METHODS FOR PRODUCING PRIMORDIAL GERM CELL-LIKE CELLS | Glaxosmithkline Intellectual Property Development Limited | KIM, TAEYOON | §102§103§112 | Non-Final OA | — | Pending | Oct 29, 2024 | |
| 18857803 | MESENCEPHALIC ASTROCYTE-DERIVED NEUROTROPHIC FACTOR (MANF) FOR INCREASING MUSCLE REGENERATION | Gulbenkian Institute For Molecular Medicine | CANDELARIA, JULIANA IRENE | 1634 | §102§112 | Non-Final OA | — | Pending | Oct 17, 2024 |
| 18912410 | METHODS OF TREATING EGFRVIII EXPRESSING GLIOBLASTOMAS | The Regents of the University of California | TIWARI, VYOMA SHUBHAM | 1634 | §112 | Final Rejection | — | Pending | Oct 10, 2024 |
| 18903947 | T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | Cue Biopharma, Inc. | ESPINOSA, CLAUDIA EDILMA | 1654 | §103§112Other | Non-Final OA | — | Pending | Oct 01, 2024 |
| 18890620 | TSPO Binders | The University Court of the University of Edinburgh | DONOHUE, SEAN R | 1618 | §102§103 | Final Rejection | — | Pending | Sep 19, 2024 |
| 18843688 | COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS | Immunophage Biotech (Shanghai) Co., Ltd. | ROCHELLE, CIERRA MARIE | 1627 | §103§112 | Non-Final OA | — | Pending | Sep 03, 2024 |
| 18806599 | Bacteria-Based Protein Delivery | Universitaet Basel | AMICK, THOMAS RUSSE | §102Other | Non-Final OA | — | Pending | Aug 15, 2024 | |
| 18729383 | A Machine Learning Pipeline for Highly-Sensitive Assessment of Rotator Cuff Function | The Regents of the University of California | KRETZER, KYLE W. | 3791 | §101§103§112 | Final Rejection | — | Pending | Jul 16, 2024 |
| 18725112 | Application of Polypeptide in Preparation of Product for Preventing or Treating Skin Injury Diseases | Sichuan Gooddoctor Panxi Pharmaceutical Co., Ltd. | KATAKAM, SUDHAKAR | 1658 | §112DP | Non-Final OA | — | Pending | Jun 27, 2024 |
| 18719710 | NOVEL SALT OF 1-SULFONYL PYRROLE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Ildong Pharmaceutical Co., Ltd. | JAVANMARD, SAHAR | 1622 | §102§103§112 | Non-Final OA | — | Pending | Jun 13, 2024 |
| 18716761 | CLOSO-DODECAIODODECABORATE COMPLEXES AND METHODS OF USE FOR SAME | The Regents of the University of California | JONES, DAMERON LEVEST | 1618 | §103§112 | Non-Final OA | — | Pending | Jun 05, 2024 |
| 18716045 | An Automated Process for Optimizing Spinal Cord Stimulation | The Regents of the University of California | COLLARD JR, DWANE EDWARD | 3792 | §102§103§112 | Non-Final OA | — | Pending | Jun 03, 2024 |
| 18658264 | Methods for Representing Data Analysis and Systems for Same | The Regents of the University of California | SILVERMAN, SETH ADAM | 2172 | §103 | Final Rejection | 12d | Pending | May 08, 2024 |
| 18657366 | Methods of Producing Size-Selected Nucleic Acid Libraries and Compositions and Kits for Practicing Same | The Regents of the University of California | BUNKER, AMY M | 1684 | §103§112 | Non-Final OA | — | Pending | May 07, 2024 |
| 18653683 | MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | Cue Biopharma, Inc. | ZOU, NIANXIANG | 1671 | §103§112DP | Non-Final OA | — | Pending | May 02, 2024 |
| 18650535 | Anti-Abeta Therapeutic Vaccines | Ac Immune SA | KIM, YUNSOO | 1641 | §102§103§112Other | Non-Final OA | — | Pending | Apr 30, 2024 |
| 18649688 | CRY PROTEIN CRYSTALS AND METHODS OF USE | BATTELLE MEMORIAL INSTITUTE | JOHNSON, TIRONE DEREK | 1675 | §102§103 | Non-Final OA | — | Pending | Apr 29, 2024 |
| 18703256 | Coxsackievirus B Compositions and Methods Of Use Thereof | Vactech OY | SIFFORD, JEFFREY MARK | 1671 | §101§103§112 | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18702756 | Wearable Non-Invasive Central Nervous System Neuromodulator and Methods for Using Same | Spinex Inc. | KOWALKOWSKI, FIONA MARGARET | 3792 | §102§103 | Non-Final OA | 2d overdue | Pending | Apr 18, 2024 |
| 18696922 | Anti-Human Astrovirus Antibodies and Related Compositions and Methods | Universidad Nacional Autónoma De México | NICKOL, GARY B | 1643 | §102§103§112 | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18690688 | Lithium Sulfur Cell | Cambridge Enterprise Limited | D'ANIELLO, NICHOLAS P | 1725 | §102§112 | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18690533 | Suppression of Neurodegeneration with Zinc Transporter Protein 7 | The Regents of the University of California | CESARE, JOSEPH DAVID | 1675 | §103§112 | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18688602 | STEROL THERAPY | Jena University Hospital | KIM, SEONG JONG | 1623 | §101§102§103§112 | Non-Final OA | — | Pending | Mar 01, 2024 |
| 18682740 | Vaccine Antigen | Macfarlane Burnet Institute For Medical Research And Public Health Limited | CHESTNUT, BARRY A | 1672 | §102§112 | Non-Final OA | — | Pending | Feb 09, 2024 |
| 18418050 | MULTI-CBV VACCINE FOR PREVENTING OR TREATING TYPE I DIABETES | Vactech OY | CHEN, STACY BROWN | 1672 | §112 | Final Rejection | 11d overdue | Pending | Jan 19, 2024 |
| 18580141 | USE OF A STROMAL ANTIGEN TO DELIVER CELL-BASED CANCER THERAPY TO A SOLID TUMOR | The Regents of the University of California | ABEYRATNE-PERERA, HASHANTHI KOMITIGE | §102§112 | Non-Final OA | — | Pending | Jan 17, 2024 | |
| 18579775 | A Surface Audio-Visual Biofeedback (SAVB) System for Motion Management | The Board Of Trustees Of The Leland Stanford Junior University | HON, MING Y | 2666 | §103 | Non-Final OA | — | Pending | Jan 16, 2024 |
| 18578617 | Compounds for Modulating Epithelial 15-(S)-Lipoxygenase-2 and Methods of Use for Same | The Regents of the University of California | KUCKLA, ANNA GRACE | 1626 | §103§112 | Final Rejection | — | Pending | Jan 11, 2024 |
| 18391501 | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | The Governors of the University of Alberta | FOLEY, SHANON A | 1671 | §103§112 | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18544206 | Method of Neural Intervention for the Treatment of Affective Neuropsychiatric Disorders | The Regents of the University of California | EDWARDS, PHILIP CHARLES | 3792 | §103 | Final Rejection | — | Pending | Dec 18, 2023 |
| 18570390 | Rippled Antiparallel Cross-Beta Dimers and Related Materials, Compositions and Methods | The Regents of the University of California | KOMATSU, LI N | 1658 | §102§112 | Non-Final OA | — | Pending | Dec 14, 2023 |
| 18568243 | Treatment or Prevention of Ischaemia Reperfusion Injury | Cambridge Enterprise Limited | NEAGU, IRINA | 1629 | §103DP | Final Rejection | — | Pending | Dec 07, 2023 |
| 18529858 | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | The Governors of the University of Alberta | JADHAO, SAMADHAN JAISING | 1672 | §103§112DP | Non-Final OA | — | Pending | Dec 05, 2023 |
| 18523548 | Compounds and Methods for Use in Detecting Gabapentin | Ark Diagnostics, Inc. | HAQ, SHAFIQUL | 1678 | §103§112DP | Non-Final OA | — | Pending | Nov 29, 2023 |
| 18565049 | Polymeric Antifouling Coating with Antimicrobial Peptides | The University of British Columbia | JOHNSON, CHRISTOPHER LINDSAY | 1691 | §102§103 | Non-Final OA | — | Pending | Nov 28, 2023 |
| 18520057 | E1E2 HCV VACCINES AND METHODS OF USE | The Governors of the University of Alberta | ZOU, NIANXIANG | 1671 | §103 | Final Rejection | — | Pending | Nov 27, 2023 |
| 18561981 | Methods And Devices For Real-Time Word And Speech Decoding From Neural Activity | The Regents of the University of California | PADDA, ARI SINGH KANE | 3791 | §101§103§112 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18288793 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | Nanjing Immunophage Biotech Co., Ltd. | LEE, ANDREW P | 1691 | §112 | Non-Final OA | — | Pending | Oct 27, 2023 |
| 18288545 | Linear DNA with Enhanced Resistance Against Exonucleases | 4Basebio UK Ltd. | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §101§103§112Other | Non-Final OA | — | Pending | Oct 26, 2023 |
| 18384266 | WATER DISPERSIBLE GRANULE ACYLHYDRAZONE APYRASE INHIBITOR FORMULATION | Texas Crop Science, Inc. | VIGIL, TORIANA NICHOLE | 1612 | §103 | Final Rejection | — | Pending | Oct 26, 2023 |
| 18382419 | SUSPENSION CONCENTRATE ACYLHYDRAZONE APYRASE INHIBITOR FORMULATION | Texas Crop Science, Inc. | ARMSTRONG, SUSANNAH SIPPLE | 1616 | §103§112DP | Final Rejection | 113d overdue | Pending | Oct 20, 2023 |
| 18287604 | Thermally Stable Lipid-Nucleic Acid Molecule Formulations Utilising Metal Organic Framework (MOF) Shells | Commonwealth Scientific And Industrial Research Organisation | ARNOLD, ERNST V | 1613 | §103DP | Non-Final OA | — | Pending | Oct 19, 2023 |
| 18287094 | Closed-Loop Neuromodulation for the Treatment of Affective Neuropsychiatric Disorders | The Regents of the University of California | MARLEN, TAMMIE K | 3792 | §103 | Final Rejection | — | Pending | Oct 16, 2023 |
| 18551553 | Pharmaceutical Combinations for Treating Cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | DRISCOLL, MAUREEN VARINA | 1644 | §112DP | Final Rejection | — | Pending | Sep 20, 2023 |
| 18468639 | METHOD FOR DETECTING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | The Regents of the University of California | ESSEX, LAURA ANN | 1675 | §112DP | Final Rejection | — | Pending | Sep 15, 2023 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial75.8% of resolved applications prosecuted by Bozicevic, Field & Francis LLP were allowed, across 8,797 applications in USPTO records.
3.96 office actions per allowed application on average.
94 pending office actions as of October 2026, for 43 clients, before 88 examiners in 47 art units.
